Log in to search using one of your social media accounts:

Top Melanoma Studies to Be Presented at ASCO Top Melanoma Studies to Be Presented at ASCO
Dr Jeffrey Weber previews five melanoma treatment studies that he considers the ones to watch; one, he predicts, will be practice-changing.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Developments in melanoma treatment
A review of established and novel therapeutic approaches for malignant melanoma, including the roles of targeted therapies and immunotherapy and potential side-effects. (Source: GP Online Education)
Source: GP Online Education - May 24, 2017 Category: Primary Care Tags: 15.10 Skin Problems Source Type: news

Tracking cancer's signaling pathways
(University of Erlangen-Nuremberg) Malignant melanoma is one of the most common and dangerous types of cancer. Researchers at Friedrich-Alexander Universit ä t Erlangen-N ü rnberg investigated how and why brown pigmented moles turn into malignant melanoma using innovative robot technology. The insights gained can simplify methods of diagnosis in the future; furthermore, they suggest that certain cosmetic products and creams should be avoided. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 23, 2017 Category: Cancer & Oncology Source Type: news

Skin color no shield against skin cancer
(Rush University Medical Center) The misconception that people with more pigment -- called melanin -- in their skin cells are protected from cancer-causing ultra-violet rays can be deadly. Melanoma, the least common form of skin cancer but also the deadliest, are more likely to be caused by genetics than the sun. Thus too many people of color don't think to look for changing moles that can be fatal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 23, 2017 Category: International Medicine & Public Health Source Type: news

Erectile Dysfunction Drugs Again Cleared of Melanoma Risk Erectile Dysfunction Drugs Again Cleared of Melanoma Risk
Another analysis of published data does not support a causal link between erectile dysfunction drugs and increased melanoma risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CNIO researcher funded by Melanoma Research Alliance to study brain metastasis in melanoma
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Manuel Valiente, head of the Brain Metastasis Group at the Spanish National Cancer Research Centre (CNIO), has been funded in the 2017 grant cycle by the Melanoma Research Alliance (MRA), the largest private funder of melanoma research. The research, titled 'Blocking melanoma brain metastasis by targeting the microenvironment', will focus on investigate actionable targets that will lead to more efficient design of anticancer treatments for patients with metastatic melanoma to the brain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 22, 2017 Category: Cancer & Oncology Source Type: news

Researchers Say PDE5 Inhibitors Don ’ t Cause Melanoma
Any connection appears to be due to detection bias, investigators conclude (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 20, 2017 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Nursing, Oncology, Pharmacy, Urology, Journal, Source Type: news

Antibody for fighting cancer emerges
While studying the underpinnings of multiple sclerosis, investigators came across important clues for how to treat a very different disease: cancer. Researchers describe an antibody that can precisely target regulatory T cells which in turn unleashes the immune system to kill cancer cells. The team reports that the antibody decreased tumor growth in models of melanoma, glioblastoma and colorectal carcinoma, making it an attractive candidate for cancer immunotherapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 19, 2017 Category: Science Source Type: news

Study Refutes Viagra-Melanoma Link
Data shows no connection between impotence drug and deadly skin cancer, after all (Source: WebMD Health)
Source: WebMD Health - May 19, 2017 Category: Consumer Health News Source Type: news

Latest Keytruda Approval Promising for Mesothelioma Patients
The U.S. Food and Drug Administration (FDA) expanded its approval of pembrolizumab for first-line treatment of metastatic non-small cell lung cancer last week, moving it closer to becoming a viable treatment option for patients with pleural mesothelioma. Pembrolizumab is marketed by Merck & Co. under the brand name Keytruda. It helps the body’s immune system detect and destroy cancer cells. The FDA approved its first-line use in combination with pemetrexed and carboplatin, two chemotherapy agents used regularly for mesothelioma. Pembrolizumab, the most well-known immunotherapy drug, is being studied for use with...
Source: Asbestos and Mesothelioma News - May 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: carboplatin chemotherapy for mesothelioma Dr. Raymond Wong Dr. Tawee Tanvetyanon FDA approval Keytruda first line treatment for mesothelioma Hodgkin lymphoma jimmy carter keytruda clinical trial keytruda for mesothelioma melanoma Mer Source Type: news

Study Refutes Viagra - Melanoma Link
Data shows no connection between impotence drug and deadly skin cancer, after all (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 19, 2017 Category: Cancer & Oncology Tags: Oncology, Reproductive Medicine, News, Source Type: news

Study Refutes Viagra-Melanoma Link
Data shows no connection between impotence drug and deadly skin cancer, after all Source: HealthDay Related MedlinePlus Pages: Erectile Dysfunction, Medicines, Melanoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 19, 2017 Category: Consumer Health News Source Type: news

Erectile dysfunction medicines do not cause melanoma, analysis of large studies finds
Use of the erectile dysfunction drug Viagra does not cause the development of melanoma, a deadly form of skin cancer, a new report concludes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 19, 2017 Category: Science Source Type: news

Study Refutes Viagra-Melanoma Link
FRIDAY, May 19, 2017 -- Some good news for sexually active older men: Viagra and related erectile dysfunction drugs do not increase the risk of deadly melanoma skin cancer, researchers report. " Physicians should still screen for melanoma risk, but... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2017 Category: General Medicine Source Type: news

Study Refutes Viagra-Melanoma Link
Title: Study Refutes Viagra-Melanoma LinkCategory: Health NewsCreated: 5/19/2017 12:00:00 AMLast Editorial Review: 5/19/2017 12:00:00 AM (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - May 19, 2017 Category: Primary Care Source Type: news

Erectile dysfunction medicines do not cause melanoma, analysis of large studies finds
(NYU Langone Medical Center / New York University School of Medicine) Use of the erectile dysfunction drug Viagra does not cause the development of melanoma, a deadly form of skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2017 Category: Cancer & Oncology Source Type: news

Antibody for fighting cancer emerges
(Brigham and Women's Hospital) While studying the underpinnings of multiple sclerosis, investigators at Brigham and Women's Hospital came across important clues for how to treat a very different disease: cancer. Researchers describe an antibody that can precisely target regulatory T cells which in turn unleashes the immune system to kill cancer cells. The team reports that the antibody decreased tumor growth in models of melanoma, glioblastoma and colorectal carcinoma, making it an attractive candidate for cancer immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2017 Category: Cancer & Oncology Source Type: news

Study Refutes Viagra-Melanoma Link
Data shows no connection between impotence drug and deadly skin cancer, after all (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - May 19, 2017 Category: Cancer & Oncology Source Type: news

First-ever global study finds massive health care inequity
A first-ever global study finds massive inequity of access to and quality of health care among and within countries, and concludes people are dying from causes with well-known treatments. For example, on a scale of 1 to 100 for health care access and quality, Norway and Australia each scored 90 overall, among the highest in the world. However, Norway scored 65 in its treatment for testicular cancer, and Australia scored 52 for treating non-melanoma skin cancer. (Source: World Pharma News)
Source: World Pharma News - May 18, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Data for KEYTRUDA ® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. Research with KEYTRUDA in Monotherapy and in Combination Includes Findings in Non-Small Cell Lung Cancer (NSCLC), Melanoma, Urothelial Carcinoma, Microsatellite-Instability High (MSI-H) Cancers, Gastric Cancer and Breast Cancer New Overall Survival Data to be Presented in NSCLC, Melanoma and Urothelial CarcinomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, will be presented at the 53rd An...
Source: Merck.com - Corporate News - May 17, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news

Binimetinib/Encorafenib Combination Effective in BRAF-Mutant Melanoma
Treatment with the combination of the MEK inhibitor binimetinib and the BRAF inhibitor encorafenib resulted in a superior progression-free survival for patients with advanced, unresectable BRAF-mutated melanoma compared with treatment with encorafenib alone. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news

Adoptive T-Cell Therapy Induced Response in Metastatic Uveal Melanoma
More than one-third of patients with metastatic uveal melanoma had objective tumor regression when treated with adoptive transfer of autologous tumor-infiltrating lymphocytes. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news

Circulating Th17.1 Cells in Melanoma Tied to Sarcoidosis
Elevation in Th17.1 cells prior to administration of PD - 1 checkpoint tx, onset of symptomatic sarcoidosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 15, 2017 Category: Cancer & Oncology Tags: Dermatology, Internal Medicine, Oncology, Pathology, Pulmonology, Rheumatology, Journal, Source Type: news

Norah O'Donnell opens up about melanoma diagnosis
As summer approaches, the "CBS This Morning" co-host is sharing the story of her stunning and scary melanoma diagnosis (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 15, 2017 Category: Consumer Health News Source Type: news

What to know about melanoma and how to protect yourself
In the June issue ofGood Housekeeping, Norah O'Donnell writes about her surprising melanoma diagnosis. Melanoma is the most serious form of skin cancer, and early detection made all the difference for O'Donnell. Her dermatologist, Dr. Elizabeth Hale, a clinical associate professor of dermatology at NYU Langone Medical Center in New York, joins "CBS This Morning" to discuss the risks and protection. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 15, 2017 Category: Consumer Health News Source Type: news

OncoSec and Merck to begin Phase II combination trial to treat metastatic melanoma
US-based biotechnology company OncoSec has entered a clinical trial collaboration and supply agreement with Merck to begin the Phase II PISCES clinical trial of ImmunoPulse IL-12 and keytruda combination for the treatment of patients with metastatic … (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news

Can Psychedelic Drugs Treat Mental Illness? Scientists Need Your Help To Find Out.
To the federal government, psychedelic drugs like LSD, MDMA (also known as Ecstasy or Molly in its street forms), and psilocybin (the psychoactive ingredient in mushrooms) are dangerous Schedule I substances with a high potential for abuse and no medical value. But leading psychedelic researchers paint a much different picture ― one of fascinating compounds with the power to rewire the human brain and possibly revolutionize treatment for a number of debilitating mental health issues. We’ve yet to find a conclusive answer that can prove either side right or wrong, though initial indications suggest it’s fair t...
Source: Science - The Huffington Post - May 10, 2017 Category: Science Source Type: news

Can Psychedelic Drugs Treat Mental Illness? Scientists Need Your Help To Find Out.
To the federal government, psychedelic drugs like LSD, MDMA (also known as Ecstasy or Molly in its street forms), and psilocybin (the psychoactive ingredient in mushrooms) are dangerous Schedule I substances with a high potential for abuse and no medical value. But leading psychedelic researchers paint a much different picture ― one of fascinating compounds with the power to rewire the human brain and possibly revolutionize treatment for a number of debilitating mental health issues. We’ve yet to find a conclusive answer that can prove either side right or wrong, though initial indications suggest it’s fair t...
Source: Healthy Living - The Huffington Post - May 10, 2017 Category: Consumer Health News Source Type: news

OncoSec inks deal with Merck to study drug-device therapy for metastatic melanoma
OncoSec Medical (NSDQ:ONCS) said today that it inked a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate the combination of its ImmunoPulse IL-12 electroporation device with Merck’s Keytruda therapy in a Phase II clinical trial. The trial aims to evaluate the drug-device combination in patients with metastatic melanoma – specifically patients who experienced disease progression after previous treatment with an anti-PD-1 therapy. OncoSec’s electroporation device delivers a sequence of short-duration electrical pulses to increase the cancer cell membrane&rsqu...
Source: Mass Device - May 10, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Biotech Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat OncoSec Medical Source Type: news

Laser, sound waves provide live views of organs in action
Biomedical engineers are now able to take a live, holistic look at the inner workings of a small animal with enough resolution to see active organs, flowing blood, circulating melanoma cells and firing neural networks. The technique uses the best of both light and ultrasound, breaking long-standing resolution and speed barriers in small-animal whole-body imaging, providing full cross-sectional view of a small animal's internal functions in real-time. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 10, 2017 Category: Science Source Type: news

Boulder biotech shares rise with 'positive' melanoma drug results
Shares in Array BioPharma Inc. were soaring in early Wednesday trading, even though the company announced a bigger loss and smaller third-quarter revenues compared with last year. That's because the Boulder biotech announced "positive" results from a study of its drug targeting unresectable or metastatic melanoma. The study results "represents a potential important addition to the ... treatment landscape for patients with BRAF-mutant melanoma," said Ron Squarer, CEO, in a statement. Array said… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 10, 2017 Category: Pharmaceuticals Authors: Ben Miller Source Type: news

Researchers have a better understanding of how advanced melanoma resists immunotherapy
FINDINGSA new study by scientists at the UCLA Jonsson Comprehensive Cancer Center could be a significant step toward understanding how certain cases of advanced melanoma shield themselves from pembrolizumab, the FDA-approved treatment that harnesses the immune system to attack the disease.The researchers, led by UCLA ’s Dr. Antoni Ribas, studied how melanoma cancer cells react to the interferon gamma pathway, which guides cell signaling and can affect the way cancer cells react to pembrolizumab. The team then discovered and mapped out the molecules involved in the signaling pathway. The findings lay the ground work f...
Source: UCLA Newsroom: Health Sciences - May 10, 2017 Category: Universities & Medical Training Source Type: news

Scan saves a lot of trouble: Tips to check your skin for common W signs of skin cancer
DESPITE rates of melanoma rising rapidly in the UK, not enough of us know how to check our skin for common W signs of cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - May 9, 2017 Category: Consumer Health News Source Type: news

'Juicing' T cells with small molecules enhances immune response against melanoma
(Medical University of South Carolina) Medical University of South Carolina investigators report in the April 20, 2017 JCI Insight that 'juicing' Th17 cells with FDA-approved small moleculeβ-catenin and p110δ inhibitors during in vitro expansion for adoptive T cell therapy profoundly improves their therapeutic properties. 'Juicing' T cells with these drugs enhanced memory stemness, diminished regulatory elements and augmented function in vivo, dramatically enhancing antitumor effectiveness in a mouse model of melanoma. These findings highlight novel avenues for next-generation immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2017 Category: Cancer & Oncology Source Type: news

Platelets suppress T cell immunity against cancer
Cancer researchers report that blood platelets blunt the immune response to cancer. Genetic inactivation of platelets improved the ability of T cells to fight melanoma in preclinical tests. Adoptive T cell therapies for cancer could be enhanced when combined with common antiplatelet drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2017 Category: Science Source Type: news

New microscopic technique could help detect, diagnose metastatic melanomas
The fight against skin cancer just got a new weapon. Researchers have devised a new tool to detect and analyze single melanoma cells that are more representative of the skin cancers developed by most patients. The study outlines the new techniques that could lead to better and faster diagnoses for the life-threatening disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2017 Category: Science Source Type: news

MRI detects cause of vision problems in astronauts
MRI scans of astronauts who spent time at the International Space Station confirm...Read more on AuntMinnie.comRelated Reading: DWI-MRI assists proton beam therapy for ocular melanoma MRI shows space travel's effect on astronauts' eyes and brains (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 5, 2017 Category: Radiology Source Type: news

Platelets suppress T cell immunity against cancer
(Medical University of South Carolina) In the May 5, 2017, issue of Science Immunology, cancer researchers at the Medical University of South Carolina report that blood platelets blunt the immune response to cancer. Genetic inactivation of platelets improved the ability of T cells to fight melanoma in preclinical tests. Adoptive T cell therapies for cancer could be enhanced when combined with common antiplatelet drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 5, 2017 Category: Cancer & Oncology Source Type: news

New microscopic technique could help detect, diagnose metastatic melanomas
The fight against skin cancer just got a new weapon. Researchers have devised a new tool to detect and analyze single melanoma cells that are more representative of the skin cancers developed by most patients. The study outlines the new techniques that could lead to better and faster diagnoses for the life-threatening disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 4, 2017 Category: Science Source Type: news

Pigmented Lesion Assay Aids Melanoma Biopsy Decisions Pigmented Lesion Assay Aids Melanoma Biopsy Decisions
Use of a gene-based pigmented lesion assay (PLA) may result in fewer biopsies for benign lesions and greater accuracy in identifying melanomas, researchers say.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 4, 2017 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news

OncoBreak: AHCA Opposition; NIH Funding; Melanoma Awareness
(MedPage Today) -- News, features, and commentary about cancer-related issues (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 4, 2017 Category: American Health Source Type: news

New microscopic technique could help detect, diagnose metastatic melanomas
(University of Missouri-Columbia) The fight against skin cancer just got a new weapon. Researchers at the University of Missouri have devised a new tool to detect and analyze single melanoma cells that are more representative of the skin cancers developed by most patients. The study, recently reported in Analyst published by the Royal Society of Chemistry, outlines the new techniques that could lead to better and faster diagnoses for the life-threatening disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2017 Category: Global & Universal Source Type: news

New unexpected key player in melanoma development identified
Identification and functional validation of proteins involved in tumorigenesis are essential steps toward advancing cancer precision medicine. Scientists now report the important role for FES in the initiation and progression of melanoma, a malignant type of skin cancer, that is notoriously quick to metastasize and that responds poorly to existing cancer treatments. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 3, 2017 Category: Science Source Type: news

A new unexpected key player in melanoma development identified
(VIB (the Flanders Institute for Biotechnology)) In The Journal of Clinical Investigation researchers from VIB, KU Leuven (Belgium) together with colleagues from INSERM (France) now report the important role for FES in the initiation and progression of melanoma, a malignant type of skin cancer, that is notoriously quick to metastasize and that responds poorly to existing cancer treatments. Unexpectedly the expression of FES, which encodes a kind of protein better known for their ability to promote cancer development-, is lost in a large fraction of human melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2017 Category: Cancer & Oncology Source Type: news

Mysterious molecule's function in skin cancer identified
(Sanford-Burnham Prebys Medical Discovery Institute) SBP researcher Ranjan Perera uncovered the M.O. of a mysterious molecule called SPRIGHTLY that acts as a hub for cancer-related genes in the nucleus. The study identified 'major' RNA binding partners -- genes already implicated in a variety of cancers. In a mouse model of melanoma, tumors with reduced SPRIGHTLY grew more slowly, indicating use as a therapeutic target or biomarker. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 3, 2017 Category: Biology Source Type: news

Emerging Therapies for Uveal Melanoma: Ophthalmology Times
(MedPage Today) -- Also: avoiding ruptures during deep anterior lamellar keratoplasty (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 2, 2017 Category: American Health Source Type: news

Too MUCH sunscreen 'is making us vitamin D deficient'
The finding, by California's Touro University, is a staggering claim as the nation battles rising rates of melanoma, a deadly form of skin cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - May 1, 2017 Category: Consumer Health News Source Type: news

Dr. Neville Sanjana receives 2017 melanoma research alliance young investigator award
(New York Genome Center) Dr. Sanjana's three-year grant was awarded for his research entitled " A human T cell genetic screen for melanoma immunotherapy, " which aims to characterize genetic mutations that lead to immunotherapy resistance in melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2017 Category: Global & Universal Source Type: news

Be smart in the sun and still have fun
Many teenagers, and sometimes their parents, think melanoma won't happen to people under 20, so skin cancer cases in young people aren't detected as early as physicians would like. To get the message out to kids of all ages about the importance of skin cancer prevention, Mayo Clinic?created a cartoon-style public service announcement (PSA), "Have [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 1, 2017 Category: Databases & Libraries Source Type: news

Kids' Sun Safety Means'Slip, Slap, Slop '
FRIDAY, April 28, 2017 -- Children spend a lot of time outside in the summer, so parents need to stay on top of their sun protection, a skin cancer expert advises. Much of a person's risk for melanoma -- the deadliest form of skin cancer -- comes... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 28, 2017 Category: Journals (General) Source Type: news